Prostate Cancer Diagnostics Industry is projected to witness a CAGR of 12.4% during the period 2023-2032. This progression can be attributed to the increasing popularity of prostate cancer diagnostic tests.
Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders Annual General Meeting at the company s premises on May 16, 2023. A total of 34,075,774 shares were represented at the. | May 17, 2023